Zimmer Biomet (ZBH) Q4 Earnings and Revenues Top Estimates

Core Insights - Zimmer Biomet (ZBH) reported quarterly earnings of $2.42 per share, exceeding the Zacks Consensus Estimate of $2.38 per share, and showing an increase from $2.31 per share a year ago, resulting in an earnings surprise of +1.70% [1] - The company achieved revenues of $2.24 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 1.87% and up from $2.02 billion year-over-year [2] Earnings Performance - Over the last four quarters, Zimmer has consistently surpassed consensus EPS estimates, achieving this four times [2] - The company also topped consensus revenue estimates three times in the same period [2] Stock Performance and Outlook - Zimmer shares have declined approximately 0.2% since the beginning of the year, while the S&P 500 has gained 1.7% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the outlook for earnings estimates [4][6] Earnings Estimates - The current consensus EPS estimate for the upcoming quarter is $1.88 on revenues of $2.05 billion, and for the current fiscal year, it is $8.41 on revenues of $8.54 billion [7] Industry Context - The Medical - Products industry, to which Zimmer belongs, is currently ranked in the bottom 29% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research suggests that trends in earnings estimate revisions are strongly correlated with near-term stock movements, which could impact Zimmer's performance [5]